Vasoactive Hormone Stratification for Patient Medication Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating diseases related to endothelial function/dysfunction are inadequate in identifying patient subgroups that may experience adverse effects from certain medications, leading to unnecessary or harmful treatments.
Innovation Solution
A method for stratifying patients based on the concentration of vasoactive hormone precursors and fragments in bodily fluids, allowing for the identification of responders and non-responders to specific medications, thereby avoiding harmful medication administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If vasoactive hormone measurements are used to stratify patients, then treatment precision is improved, but device complexity and measurement cost increase
Solution Approach 1:
The patent measures different vasoactive hormones (BNP, NT-proBNP, ANP, copeptin, endothelin-1, adrenomedullin) at various concentration thresholds to stratify patients into different risk groups. By changing the measurement parameters (which hormone to measure, what concentration threshold to use), the system achieves precise patient stratification without requiring a single complex device,而是 using standardized immunoassay techniques that can be implemented in routine clinical laboratories.
2Reliability
If comprehensive vasoactive hormone profiling is performed, then patient outcome prediction is improved, but measurement time and cost increase
Solution Approach 1:
The patent segments the vasoactive hormone measurement into discrete, measurable components (BNP, NT-proBNP, ANP, copeptin, endothelin-1, adrenomedullin) with specific concentration thresholds. This segmentation allows clinicians to measure only the relevant markers for each patient's condition rather than performing a comprehensive panel on every patient, reducing measurement time while maintaining prognostic accuracy.
Solution Approach 2:
The patent applies partial action by selecting specific vasoactive hormone measurements based on clinical indication rather than measuring all possible markers. For example, BNP/NT-proBNP may be measured for heart failure patients while endothelin-1 may be measured for pulmonary hypertension patients, avoiding unnecessary measurements and reducing overall measurement time and cost.
3Object-affected harmful factors
If patient stratification is implemented, then harmful medication effects are reduced, but treatment protocol complexity increases
Solution Approach 1:
The patent applies local quality by tailoring treatment recommendations to specific patient subgroups defined by their vasoactive hormone profiles. Instead of a uniform treatment protocol for all patients, the system provides localized treatment guidance for each stratification category (e.g., different medication recommendations for patients with elevated BNP versus those with elevated endothelin-1), thereby reducing adverse effects while managing protocol complexity through targeted rather than universal approaches.
Data Source
Figure 1A~1D
Figure 2A~2D
Figure 3A~3D
AI summary
The present invention relates to a method for the stratification of a subject having an acute or a chronic disease, wherein said disease effects endothelial function/dysfunction, comprising the steps of (i) taking a sample of bodily fluid from said subject; (ii) determining in said sample of bodily fluid the concentration of a vasoactive hormone or fragments thereof or precursors or fragments thereof having a length of at least 12 amino acid residues; (iii) stratifying said subjects into either of the categories: (a) responder to a medication for treatment of said disease, (b) non-responder to a medication for treatment of said disease not showing an unfavourable effect after having received said medication; (c) subjects showing an unfavourable effect after having received said medication. The invention also relates to the use of an antibody or a functional fragment thereof in the method according to the invention.